David Shaw’s PTC Therapeutics PTCT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2018
Q3
– Sell
-54,000
Closed -$1.82M – 3920
2018
Q2
$1.82M Sell
54,000
-1,800
-3% -$56.1K ﹤0.01% 2293
2018
Q1
$1.51M Buy
+55,800
New +$1.41M ﹤0.01% 2228

Other funds holding PTCT

David Shaw's PTCT Position: Q3 2026 in Review

David Shaw reduced its PTC Therapeutics (PTCT) stake by 60% in Q3 2026, selling an estimated $67.7M and leaving 618,723 shares worth $40.1M. The position accounts for 0.02% of the portfolio, ranked #887.

David Shaw first reported a position in PTCT in Q2 2014 and has held it in 46 quarters since. The position peaked at $133M in Q3 2025. 361 funds tracked by Wall St. Rank hold PTCT as of Q3 2026.

  • David Shaw held 618,723 shares of PTC Therapeutics worth $40.1M as of Q3 2026.
  • David Shaw sold 930,196 PTC Therapeutics shares in Q3 2026, an estimated $67.7M.
  • PTC Therapeutics made up 0.02% of David Shaw's portfolio in Q3 2026, its #887 holding.
  • David Shaw first reported a position in PTC Therapeutics in Q2 2014 and has held it in 46 quarters since.
  • David Shaw's PTC Therapeutics position peaked at $133M in Q3 2025.
  • 361 funds tracked by Wall St. Rank held PTC Therapeutics as of Q3 2026.

Based on D.E. Shaw & Co's 13F filing for Q3 2026, filed 16 Nov 2026.